Skip to main content

Advertisement

SpringerLink
Log in

New Treatment Options for ALK-Rearranged Non-Small Cell Lung Cancer

  • Lung Cancer (HA Wakelee, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion Statement

ALK rearrangements are present in 3–5 % of patients with non-small cell lung cancer (NSCLC) and after epidermal growth factor receptor (EGFR) mutations represent the second molecular target in NSCLC to be validated through phase III clinical trials. The PROFILE 1014 international multicentre phase III trial demonstrated the superiority of crizotinib over standard chemotherapy, establishing crizotinib as standard first-line therapy for patients with advanced ALK-positive NSCLC and indicating the requirement for ALK testing to guide selection of optimal first-line therapy for non-squamous NSCLC. Despite impressive and durable responses, progression on treatment reflecting the development of acquired resistance is inevitable. There are several mechanisms of resistance including ALK kinase mutation or copy number gain, activation of bypass pathways and potentially pharmacokinetic failure of therapy (most commonly in CNS). A broad array of newer generation ALK inhibitors are in development that appear effective in the crizotinib-resistant setting including in patients with intracranial progression. These agents, including ceritinib and alectinib, have a higher potency against ALK kinase than crizotinib, activity against mutations that confer resistance to crizotinib and potentially improved CNS penetration. While in selected patients, continued therapy with crizotinib after local ablative treatments of oligo-progressive systemic or CNS disease may be an option, for many patients use of a newer generation compound will be effective. First-line treatment with newer generation ALK inhibitors may have potential advantages over sequential treatment after crizotinib; however, the optimal sequence of therapy with ALK inhibitors has not been determined and is being explored in ongoing phase III studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Paper of particular of interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science. 1994;263(5151):1281–4.

    Article  CAS  PubMed  Google Scholar 

  2. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561–6.

    Article  CAS  PubMed  Google Scholar 

  3. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007;131(6):1190–203.

    Article  CAS  PubMed  Google Scholar 

  4. Ou SH, Bartlett CH, Mino-Kenudson M, Cui J, Iafrate AJ. Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology. Oncologist. 2012;17(11):1351–75.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  5. Soda M, Takada S, Takeuchi K, Choi YL, Enomoto M, Ueno T, et al. A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci U S A. 2008;105(50):19893–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  6. Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012;13(10):1011–9. First time in human phase I study of crizotinib which first demonstrated activity of crizotinib in ALK-rearranged NSCLC.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385–94. Phase III study of crizotinib compared with either pemetrexed or docetaxel in previously treated patients with ALK gene rearrangements (PROFILE1007). This study demonstrated superiority of crizotinib over chemotherapy in this population.

    Article  CAS  PubMed  Google Scholar 

  8. Solomon BJ, Mok T, Kim D-W, Wu Y-L, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167–77. Phase III study of first line crizotinib compared with platinum-pemetrexed in newly diagnosed patients with ALK rearranged NSCLC. This study established crizotinib as standard first line treatment for patients with newly diagnosed ALK rearranged NSCLC.

    Article  PubMed  Google Scholar 

  9. Solomon B, Varella-Garcia M, Camidge DR. ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J Thorac Oncol. 2009;4(12):1450–4.

    Article  PubMed  Google Scholar 

  10. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27(26):4247–53.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311(19):1998–2006.

    Article  PubMed Central  PubMed  Google Scholar 

  12. Doebele RC, Lu X, Sumey C, Maxson DA, Weickhardt AJ, Oton AB, et al. Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer. Cancer. 2012;118(18):4502–11.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol. 2013;8(7):823–59. doi:10.1097/JTO.0b013e318290868f. Guidelines for molecular testing for ALK-rearrangements in NSCLC.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. Tsao M, Hirsch F, Yatabe Y. IASLC atlas of ALK testing in lung cancer. Aurora, CO, International Society for the Study of Lung Cancer. 2013. Description of methods for testing ALK gene rearrangements in NSCLC.

  15. Kim DK, Ahn MJ, Yang P, Liu X, De Pas T, Crino L, et al. Updated results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). Ann Oncol. 2012;23(9):402.

    Google Scholar 

  16. Kazandjian D, Blumenthal GM, Chen HY, He K, Patel M, Justice R, et al. FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements. Oncologist. 2014;19(10):e5–11.

    Article  PubMed Central  PubMed  Google Scholar 

  17. Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 2011;12(11):1004–12.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Project TCLCG, NGM NGM. A genomics-based classification of human lung tumors. Sci Transl Med. 2013;5(209):209ra153.

    Google Scholar 

  19. Solomon B. Refining the toxicity profile of crizotinib. J Thorac Oncol. 2014;9(11):1596–7.

    Article  PubMed  Google Scholar 

  20. Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014. doi:10.1056/NEJMoa1406766.

    Google Scholar 

  21. Camidge D, Ou S, Shapiro G, Otterson G, Villaruz L, Villalona-Calero M et al. Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC). J Clin Oncol. 2014;32(15).

  22. Doebele RC, Pilling AB, Aisner DL, Kutateladze TG, Le AT, Weickhardt AJ, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non–small cell lung cancer. Clin Cancer Res. 2012;18(5):1472–82. Description of mechanisms of resistance to crizotinib in ALK-rearranged NSCLC.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  23. Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon BJ, Halmos B, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med. 2012;4(120):120ra17. Description of mechanisms of resistance to crizotinib in ALK rearranged NSCLC.

    PubMed Central  PubMed  Google Scholar 

  24. Katayama R, Khan TM, Benes C, Lifshits E, Ebi H, Rivera VM, et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U S A. 2011;108(18):7535–40.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  25. Toyokawa G, Seto T. Updated evidence on the mechanisms of resistance to ALK inhibitors and strategies to overcome such resistance: clinical and preclinical data. Oncol Res Treat. 2015. doi:10.1159/000430852.

    PubMed  Google Scholar 

  26. Camidge DR, Doebele RC. Treating ALK-positive lung cancer—early successes and future challenges. Nat Rev Clin Oncol. 2012;9(5):268–77.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  27. Rossi A, Maione P, Sacco PC, Sgambato A, Casaluce F, Ferrara ML, et al. ALK inhibitors and advanced non-small cell lung cancer (review). Int J Oncol. 2014;45(2):499–508.

    CAS  PubMed  Google Scholar 

  28. Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med. 2010;363(18):1734–9.

    Article  CAS  PubMed  Google Scholar 

  29. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005;2(3), e73.

    Article  PubMed Central  PubMed  Google Scholar 

  30. Lovly CM, McDonald NT, Chen H, Ortiz-Cuaran S, Heukamp LC, Yan Y, et al. Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer. Nat Med. 2014;20(9):1027–34.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  31. Marsilje TH, Pei W, Chen B, Lu W, Uno T, Jin Y, et al. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulf onyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem. 2013. doi:10.1021/jm400402q.

    PubMed  Google Scholar 

  32. Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014;370(13):1189–97. Phase I/II study of ceritinib (previously known as LDK378) demonstrating activity in crizotinib naïve and crizotinib refractory patients with ALK rearranged NSCLC.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  33. Felip E, Kim D, Mehra R, Tan DSW, Chow LQ, Camidge DR, et al. Efficacy and safety of ceritinib in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC). Ann Oncol. 2014;25(suppl_4):iv426–70. 1295P.

    Google Scholar 

  34. Mok T, Spigel D, Felip E, de Marinis F, Ahn M-J, Groen HJM, et al. ASCEND-2: a single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ). J Clin Oncol. 2015;33(15_suppl):8059.

    Google Scholar 

  35. Felip E, Orlov S, Park K, Yu C-J, Tsai C-M, Nishio M, et al. ASCEND-3: a single-arm, open-label, multicenter phase II study of ceritinib in ALKi-naive adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC). J Clin Oncol. 2015;33(15_suppl):8060.

    Google Scholar 

  36. Gainor JFFL, Katayama R, Awad M, Lockerman EL, Schultz K, Mahmood S, et al. Evolution of resistance in ALK-positive patients treated with ALK tyrosine kinase inhibitors (TKIs). J Clin Oncol. 2014;32(5s).

  37. Kinoshita K, Asoh K, Furuichi N, Ito T, Kawada H, Hara S, et al. Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802). Bioorg Med Chem. 2012;20(3):1271–80.

    Article  CAS  PubMed  Google Scholar 

  38. Kodama T, Tsukaguchi T, Satoh Y, Yoshida M, Watanabe Y, Kondoh O, et al. Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer. Mol Cancer Ther. 2014. doi:10.1158/1535-7163.MCT-14-0274.

    Google Scholar 

  39. Seto T, Kiura K, Nishio M, Nakagawa K, Maemondo M, Inoue A, et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study. Lancet Oncol. 2013;14(7):590–8. Phase I/II study of alectinib in Japanese patients with crizotinib naïve ALK-rearranged NSCLC.

    Article  CAS  PubMed  Google Scholar 

  40. Ohe Y, Nishio M, Kiura K, Seto T, Nakagawa K, Maemondo M, et al. A phase I/II study with a CNS-penetrant, selective ALK inhibitor alectinib in ALK-rearranged non-small cell lung cancer (ALK+ NSCLC) patients (pts): updates on progression free survival (PFS) and safety results from AF-001JP. J Clin Oncol. 2015;33(15_suppl):8061.

    Google Scholar 

  41. Gadgeel SM, Gandhi L, Riely GJ, Chiappori AA, West HL, Azada MC, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol. 2014;15(10):1119–28. Phase I/II study of alectinib in western patients with ALK rearranged NSCLC who had previously received crizotinib.

    Article  CAS  PubMed  Google Scholar 

  42. Kodama T, Hasegawa M, Takanashi K, Sakurai Y, Kondoh O, Sakamoto H. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Cancer Chemother Pharmacol. 2014;74(5):1023–8.

    Article  CAS  PubMed  Google Scholar 

  43. Nanjo S, Nakagawa T, Takeuchi S, Kita K, Fukuda K, Nakada M, et al. In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell line. Cancer Sci. 2015. doi:10.1111/cas.12600.

    PubMed  Google Scholar 

  44. Gainor JF, Sherman CA, Willoughby K, Logan J, Kennedy E, Brastianos PK, et al. Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib. J Thorac Oncol. 2015;10(2):232–6. Case series demonstrating the cctivity of alectinib in leptomeningeal disease.

    Article  CAS  PubMed  Google Scholar 

  45. Katayama R, Friboulet L, Koike S, Lockerman EL, Khan TM, Gainor JF, et al. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. Clin Cancer Res. 2014;20(22):5686–96.

    Article  CAS  PubMed  Google Scholar 

  46. Ou IS, Azada M, Hsiang D, Herman J, Kain T, Siwak-Tapp C, et al. Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib. J Thorac Oncol. 2014;9(4):549–53.

    Article  Google Scholar 

  47. Gandhi L, Shaw A, Gadgeel SM, Riely G, Cetnar J, West HJ, et al. A phase II, open-label, multicenter study of the ALK inhibitor alectinib in an ALK+ non-small-cell lung cancer (NSCLC) U.S./Canadian population who had progressed on crizotinib (NP28761). J Clin Oncol. 2015;33(15_suppl):8019.

    Google Scholar 

  48. Ou S-HI, Ahn JS, De Petris L, Govindan R, Yang JC-H, Hughes BGM, et al. Efficacy and safety of the ALK inhibitor alectinib in ALK+ non-small-cell lung cancer (NSCLC) patients who have failed prior crizotinib: an open-label, single-arm, global phase 2 study (NP28673). J Clin Oncol. 2015;33(15_suppl):8008.

    Google Scholar 

  49. Zhang S, Wang F, Keats J, Ning Y, Wardwell SD, Moran L et al., editors. Abstract LB-298: AP26113, a potent ALK inhibitor, overcomes mutations in EML4-ALK that confer resistance to PF-02341066 (PF1066). AACR 101st Annual Meeting. 2010.

  50. Rivera VM, Wang F, Anjum R, Zhang S, Squillace R, Keats J et al., editors. AP26113 is a dual ALK/EGFR inhibitor: characterization against EGFR T790M in cell and mouse models of NSCLC. AACR 103rd Annual Meeting. 2012.

  51. Gettinger S, Bazhenova L, Salgia R, Langer C, Gold K, Rosell R, et al. ALK inhibitor AP26113 in patients with advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC): updated efficacy and safety data. Ann Oncol. 2014;25(suppl_4):iv426–70. 1292P.

    Google Scholar 

  52. Camidge DR, Bazhenova L, Salgia R, Langer CJ, Gold KA, Rosell R, et al. Safety and efficacy of brigatinib (AP26113) in advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC). J Clin Oncol. 2015;33(15_suppl):8062. Phase I/II study of brigatinib in ALK rearranged NSCLC.

    Google Scholar 

  53. De Braud FGM, L. Pilla L, Niger M, Damian S, Bardazza B, Martinetti A et al., editors. Phase 1 open label, dose escalation study of RXDX-101, an oral pan-Trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations. ESMO; 2014: Annals of Oncology (2014) 25 (suppl_4): iv146-iv164.

  54. Yamazaki S, Lam JL, Zou HY, Wang H, Smeal T, Vicini P. Translational pharmacokinetic-pharmacodynamic modeling for an orally available novel inhibitor of anaplastic lymphoma kinase and c-Ros oncogene 1. J Pharmacol Exp Ther. 2014;351(1):67–76.

    Article  PubMed  Google Scholar 

  55. Johnson TW, Richardson PF, Bailey S, Brooun A, Burke BJ, Collins MR, et al. Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(m etheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations. J Med Chem. 2014;57(11):4720–44.

    Article  CAS  PubMed  Google Scholar 

  56. Shaw AT, Bauer TM, Felip E, Besse B, James LP, Clancy JS et al. Clinical activity and safety of PF-06463922 from a dose escalation study in patients with advanced ALK+ or ROS1+ NSCLC. J Clin Oncol. 2015;33:Abstract 8018.

  57. Lovly CM, Heuckmann JM, de Stanchina E, Chen H, Thomas RK, Liang C, et al. Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Cancer Res. 2011;71(14):4920–31.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  58. Horn L, Blumenscheine G, Wakelee HA, Arkenau TH, Dukart G, Harrow K, et al. A phase 1 trial of X-396, a novel ALK inhibitor, in patients with advanced solid tumors. Int J Rad Oncol Biol Phys. 2014;90(5):S52–3.

    Article  Google Scholar 

  59. Wilcoxen KM, Brake RL, Saffran D, Teffera Y, Choquette D, Whittington D et al., editors. Characterization of a novel series of potent, selective inhibitors of wild type and mutant/fusion anaplastic lymphoma kinase. AACR 103rd Annual Meeting; 2012.

  60. Sachdev J, Arkenau HT, Infante JR, Mita MM, Anthony SP, Natale RB, et al. Phase (Ph) 1/2a study of TSR-011, a potent inhibitor of ALK and TRK, in advanced solid tumors including crizotinib-resistant ALK positive non-small cell lung cancer. Eur J Cancer. 2014;50(6):165.

    Article  Google Scholar 

  61. Mori M, Ueno Y, Konagai S, Fushiki H, Shimada I, Kondoh Y, et al. The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice. Mol Cancer Ther. 2014;13(2):329–40.

    Article  CAS  PubMed  Google Scholar 

  62. Heuckmann JM, Balke-Want H, Malchers F, Peifer M, Sos ML, Koker M, et al. Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. Clin Cancer Res. 2012;18(17):4682–90.

    Article  CAS  PubMed  Google Scholar 

  63. Normant E, Paez G, West KA, Lim AR, Slocum KL, Tunkey C, et al. The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models. Oncogene. 2011;30(22):2581–6.

    Article  CAS  PubMed  Google Scholar 

  64. Sequist LV, Gettinger S, Senzer NN, Martins RG, Janne PA, Lilenbaum R, et al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol. 2010;28(33):4953–60.

    Article  CAS  PubMed  Google Scholar 

  65. Socinski MA, Goldman J, El-Hariry I, Koczywas M, Vukovic V, Horn L, et al. A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res. 2013;19(11):3068–77.

    Article  CAS  PubMed  Google Scholar 

  66. Felip E, Carcereny E, Barlesi F, Gandhi L, Sequist LV, Kim S-W, et al. Phase II activity of the HSP90 inhibitor AUY922 in patients with ALK-rearranged (ALK+) or EGFR-mutated advanced non-small cell lung cancer (NSCLC). Ann Oncol. 2012;23(9):ix152. Abstract 4380.

    Article  Google Scholar 

  67. Sang J, Acquaviva J, Friedland JC, Smith DL, Sequeira M, Zhang C, et al. Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Cancer Discov. 2013;3(4):430–43.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  68. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WEE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015. doi:10.1056/NEJMoa1504627.

    PubMed  Google Scholar 

  69. Friboulet L, Li N, Katayama R, Lee CC, Gainor JF, Crystal AS, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Dis. 2014;4(6):662–73.

    Article  CAS  Google Scholar 

  70. Zou HY, Engstrom LR, Li Q, West Lu M, Tang RW, Wang H, et al. Abstract C253: PF-06463922, a novel brain-penetrating small molecule inhibitor of ALK/ROS1 with potent activity against a broad spectrum of ALK resistant mutations in preclinical models in vitro and in vivo. Mol Cancer Ther. 2013;12(11 Supplement):C253.

    Article  Google Scholar 

  71. Costa DB, Shaw AT, Ou SH, Solomon BJ, Riely GJ, Ahn MJ, et al. Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J Clin Oncol. 2015. doi:10.1200/JCO.2014.59.0539.

    Google Scholar 

  72. Ou SH, Janne PA, Bartlett CH, Tang Y, Kim DW, Otterson GA, et al. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. Ann Oncol. 2014;25(2):415–22.

    Article  PubMed  Google Scholar 

  73. Gan GN, Weickhardt AJ, Scheier B, Doebele RC, Gaspar LE, Kavanagh BD, et al. Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib. Int J Rad Oncol Biol Phys. 2014;88(4):892–8.

    Article  Google Scholar 

  74. Costa DB, Kobayashi S, Pandya SS, Yeo W-L, Shen Z, Tan W, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol. 2011;29(15):e443–5.

    Article  PubMed  Google Scholar 

  75. Weickhardt AJ, Scheier B, Burke JM, Gan G, Lu X, Bunn Jr PA, et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol. 2012;7(12):1807–14.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Laird Cameron declares that he has no conflict of interest.

Benjamin Solomon has served on advisory boards for Pfizer, Novartis, and Roche.

Human and Animal Rights and Informed Consent

Dr. Solomon has conducted studies cited in this article that have involved human subjects.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Peter MacCallum Cancer Centre, St Andrew’s Place, East Melbourne, VIC, 3002, Australia

    Laird Cameron MbChB & Benjamin Solomon MBBS, PhD, FRACP

Authors
  1. Laird Cameron MbChB
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Benjamin Solomon MBBS, PhD, FRACP
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Benjamin Solomon MBBS, PhD, FRACP.

Additional information

This article is part of the Topical Collection on Lung Cancer

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cameron, L., Solomon, B. New Treatment Options for ALK-Rearranged Non-Small Cell Lung Cancer. Curr. Treat. Options in Oncol. 16, 49 (2015). https://doi.org/10.1007/s11864-015-0367-z

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11864-015-0367-z

Keywords

Search

Navigation